Sun Pharmaceutical Industries Limited (BOM: 524715)
India
· Delayed Price · Currency is INR | Market Cap | 4.27T |
| Revenue (ttm) | 503.08B |
| Net Income (ttm) | 110.54B |
| Shares Out | n/a |
| EPS (ttm) | 46.11 |
| PE Ratio | 38.60 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,920 |
| Average Volume | 43,199 |
| Open | 1,786.40 |
| Previous Close | 1,786.15 |
| Day's Range | 1,768.90 - 1,798.85 |
| 52-Week Range | 1,319.60 - 1,960.20 |
| Beta | n/a |
| RSI | 42.23 |
| Earnings Date | Jan 27, 2025 |
About Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and othe... [Read more]
Financial Performance
In 2023, Sun Pharmaceutical Industries's revenue was 484.97 billion, an increase of 10.51% compared to the previous year's 438.86 billion. Earnings were 95.76 billion, an increase of 13.01%.
Financial StatementsNews
Sun Pharma’s subsidiary Taro to acquire Antibe Therapeutics
Sun Pharmaceutical Industries Limited, through its subsidiary TARO Pharmaceuticals Inc., has entered into an agreement to acquire 100% of Antibe Therapeutics Inc., a clinical-stage biotechnology compa...
Sensex jumps over 1,400 pts, best day in nearly 2 months
The sensex surged by 1,436 points, nearly reaching 80,000, driven by broad-based buying and short covering. Gains in banking, IT, auto and metal stocks also fuelled the rally amidst low foreign fund a...
Nifty 50 top losers today on January 2: Sun Pharmaceutical and Britannia Industries lead the decline
Indian equity markets experienced a strong rally on January 2, 2025, with the Nifty 50 and Sensex indices posting impressive gains. The broader market saw buying interest across multiple sectors, push...
Pharma sector stocks performance: Ipca Labs gains 1.23%, Biocon up 0.84%, Sun Pharma and Torrent Pharma slip over 1%
Pharma sector stocks displayed a mixed trend as of 10:33 AM. Ipca Labs led the gainers with a 1.23% rise, followed by Biocon at 0.84% and Dr. Reddy’s at 0.65%. On the downside, Sun Pharma (-1.15%), Au...
Healthcare Sector Stock Update: Sun Pharma up 1.05%, Cipla up 1.22%, Zydus Lifesciences up 2%
The healthcare sector displayed a varied performance in today’s trading session, with pharmaceutical giants leading gains while hospital operators experienced mixed trends. Gainers: Sun Pharmaceutical...
Pharma Sector Stocks: Torrent Pharma (+0.25%) rises; Glenmark (-2.29%), Aurobindo (-2.02%) decline
The pharma sector showed mixed trends during the session as of 12:15 AM. Torrent Pharma was the only gainer, rising ₹8.45 to ₹3,336.30 (+0.25%). Sun Pharma dipped ₹4.95 to ₹1,800.50 (-0.27%), and Dr. ...
Motilal Oswal’s healthcare sector picks: Sun Pharma, IPCA, Mankind, Ajanta, and Glenmark
Motilal Oswal Financial Services has highlighted key stock recommendations in the healthcare sector, projecting strong growth potential for 2024. The focus includes prominent pharmaceutical companies ...
HSBC on Indian Pharma Sector: Strong 2025 Outlook for Cipla, Sun Pharma, and Torrent Pharma
HSBC retains a positive view on Indian pharmaceutical companies, projecting strong performance in 2025 led by peak gRevlimid sales and differentiated launches in the US. Companies under HSBC’s coverag...
Brokerage radar: Ceat, Sun Pharma, Godrej Consumer Products, NHPC, Reliance, Tata Power, Lloyd Metals and PG Electroplast in focus today
Brokerage houses have shared their latest insights and price targets for several stocks across industries. Here is a summary of the reports released today, Dec 9, 2024: Ceat Brokerage House: Investec ...
Jefferies on Sun Pharma: Reiterates buy rating with Rs 2150 target, sees 19.23% upside
Jefferies has reaffirmed its ‘Buy’ rating on Sun Pharma, setting a target price of ₹2150, reflecting a potential upside of 19.23% from the current market price of ₹1,803.35. The brokerage analyzed Sun...
Nifty 50 top gainers today on 29 November: Bharti Airtel, Sun Pharmaceutical and Cipla lead the rally
On November 29, 2024, Indian equity indices made a robust comeback, erasing losses from the previous session and closing on a high note. The Nifty 50 surged past the 24,100 mark, while the Sensex rose...
Sun Pharma market cap rises Rs 12,220 crore today
Sun Pharmaceutical Industries witnessed a 2.94% rise in its stock price today, closing at Rs 1,785.20. This surge resulted in an increase of Rs 12,220 crore in the company’s market capitalization, whi...
Pharma stocks: Sun Pharma up 1.27%, Dr. Reddy’s rises 0.82%, Cipla gains 0.53%
The pharmaceutical sector saw broad-based gains in early trade on November 29, 2024, with Cipla and Sun Pharma leading the charge. Here’s a detailed look at the top pharma stocks as of 10:34 AM: Stock...
Nifty 50 top gainers today on 12 November: Trent, Infosys and Sun Pharmaceutical lead the charge
On Tuesday, Indian equity markets closed on a negative note, with the benchmark indices BSE Sensex and NSE Nifty50 both witnessing declines of over 1%. The BSE Sensex ended at 78,675.18, shedding 820....